Provisional NICE nod for Ilumetri

Ilumetri (tildrakizumab), a humanized, high-affinity interleukin (IL)-23p19 monoclonal antibody from Spanish drugmaker Almirall (BME: ALM), has been recommended by the UK's National Institute for Health and Care Excellence (NICE) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Following a single health technology assessment submission to the NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, the UK’s cost-effectiveness watchdog has completed its assessment and has now issued a Final Appraisal Determination (FAD) provisionally recommending Ilumetri as a cost-effective treatment option for the National Health Service for the patients specified in the FAD. Final NICE approval is expected in April 2019.

Jacob Anker Rasmussen, Almirall's general manager for the UK and Nordic countries, said: "The provisional recommendation by the NICE appraisal committee, who agreed that tildrakizumab is a cost-effective option, is excellent news for both dermatologists and patients. It means that dermatologists in the UK now have an additional biologic treatment option and suitable patients can now be considered for tildrakizumab".